Search Results
Jun 25, 2026, 08:03 ET EcoFlow New Product Launch Roundtable Forum Focuses on Self-Evolving Smart Energy
evolution of next-generation HEMS.HEMS: A Major Building Block of the Future Energy SystemBefore the panel discussion, Prof. Dr. rer. nat. Thomas Hamacher, Chair of Renewables and Sustainable Energy Systems and Director of the Munich Institute of Integrated Materials, Energy and Process
More news about: EcoFlow
Jun 17, 2026, 08:45 ET A Fully Permitted Gold Project in Tanzania Is Quietly Building the Team to Actually Mine It
approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions
More news about: USA News Group
Jun 17, 2026, 08:00 ET G-P Achieves ISO/IEC 42001 Certification, Setting the Global Standard for Trust and Ethical AI in Global Employment
Platform operates with the highest levels of transparency, accountability and risk management."True innovation cannot exist without trust," said Nat Natarajan, COO at G-P. "Achieving ISO/IEC 42001 certification isn't just a technical milestone for G-P, it is a testament to our foundational commitment
More news about: G-P
Jun 17, 2026, 08:00 ET G-P Achieves ISO/IEC 42001 Certification, Setting the Global Standard for Trust and Ethical AI in Global Employment
Platform operates with the highest levels of transparency, accountability and risk management."True innovation cannot exist without trust," said Nat Natarajan, COO at G-P. "Achieving ISO/IEC 42001 certification isn't just a technical milestone for G-P, it is a testament to our foundational commitment
More news about: G-P
Jun 17, 2026, 05:00 ET CHOP Scientists Engineer Personalized Cartilage Graft for Infants with Life-Threatening Airway Narrowing
P3AR0069619.Gehret et al, "A Translational Approach to Airway Reconstruction Leveraging Decellularized Meniscus and Cartilage Progenitor Cells." Nat Comm. Online June 17 2026. DOI: 10.1038/s41467-026-73680-2.About Children's Hospital of Philadelphia: A non-profit, charitable
More news about: Children's Hospital of Philadelphia
Jun 12, 2026, 14:51 ET Purchasers of Standalone Storage Device or Computer for resale in the United States from January 2003, through May 2016, may be affected by a class action lawsuit
Ltd., Magnecomp Corporation, and SAE Magnetics (H.K.) Ltd. (together, "TDK Defendants"), and NHK Spring Co., Ltd., NHK International, NAT Peripheral (Dong Guan) Co., Ltd., NAT Peripheral (Hong Kong) Co., Ltd., and NHK Spring (Thailand) Co., Ltd. (together, "NHK Defendants"). This Notice only applies to Reseller
More news about: United States District Court for the Northern District of California
Jun 11, 2026, 02:23 ET Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO
et al. A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19. Nat Commun. 2025;16:7084. doi:10.1038/s41467-025-62423-4[Appendix] Supporting Materials[Appendix 1] The Origins of XAFTY®
More news about: Hyundai Bioscience
Jun 09, 2026, 02:00 ET VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway
Keßler J, Schoder V, Häuser W. Full-spectrum extract from Cannabis sativa DKJ127 for chronic back pain: a randomized, placebo-controlled phase 3 study. Nat Med (2025), published online on September 29, 2025, doi: 10.1038/s41591-025-03977-02 Meissner W, Argoff C, Sator S, Schoder V, Karst
More news about: Vertanical
Jun 07, 2026, 14:30 ET 頭對頭:埃諾格魯肽體重降幅顯著優於司美格魯肽35%
12-B. Study number SCW0502-11222 Ji L, et al. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-7893 Mullard A. Nat Rev Drug Discov. 2023 May;22(5)347-348.
More news about: 杭州先為達生物科技股份有限公司
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
2026 ADA poster 12-B. Study number SCW0502-1122Ji L, et al. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789Mullard A. Nat Rev Drug Discov. 2023 May;22(5)347-348.
More news about: Sciwind Biosciences Co., Ltd.
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609.Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372.Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116.Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927.Vcare
More news about: Vcare PharmaTech
Jun 05, 2026, 04:52 ET A campanha "Heritage Adapts!", reconhecida pela ONU, é lançada para acelerar a adaptação climática do patrimônio até 2030
https://mma.prnewswire.com/media/745485/Nat_Geo_Logo.jpg
More news about: National Geographic Society
Jun 04, 2026, 16:15 ET UN-anerkannte Kampagne Heritage Adapts! startet, um die Klimaanpassung für das Kulturerbe bis 2030 zu beschleunigen
https://mma.prnewswire.com/media/745485/Nat_Geo_Logo.jpg
More news about: National Geographic Society
Jun 04, 2026, 16:12 ET Lancement de la campagne « Le patrimoine s'adapte ! », avec le soutien des Nations unies, pour accélérer l'adaptation du patrimoine au changement climatique d'ici à 2030
https://mma.prnewswire.com/media/745485/Nat_Geo_Logo.jpg
More news about: National Geographic Society
Jun 04, 2026, 16:07 ET La campaña Heritage Adapts! se lanza para acelerar la adaptación del patrimonio cultural al cambio climático
https://mma.prnewswire.com/media/745485/Nat_Geo_Logo.jpg
More news about: National Geographic Society
Jun 04, 2026, 06:00 ET UN-recognized campaign Heritage Adapts! launches to accelerate climate adaptation for heritage by 2030
https://mma.prnewswire.com/media/745485/Nat_Geo_Logo.jpg
More news about: National Geographic Society
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
cancer (SCLC). J Cancer. 2022;13(9):2945-2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Listen mit klinischen Studien zu Tarlatamab. US National Library of Medicine. Abgerufen
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
cancer (SCLC). J Cancer. 2022;13(9):2945-2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Liste des essais cliniques sur le tarlatamab. Bibliothèque nationale de médecine des
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
cancer (SCLC). J Cancer. 2022;13(9): 2945 – 2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9): 549 – 561.ClinicalTrials.gov. Záznamy o klinických skúšaniach tarlatamabu. US National Library of Medicine. Cit.
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
J Cancer. 2022;13(9):2945-2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Seznam klinických studií s tarlatamabem. Národní knihovna medicíny USA.
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
Laird JH, et al. Unravelling the biology of SCLC: implications for therapy (Odkrywanie biologii drobnokomórkowego raka płuca: implikacje dla terapii). Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Wpisy dotyczące badań klinicznych tarlatamabu. US National
More news about: Amgen
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
cancer (SCLC). J Cancer. 2022;13(9):2945-2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Tarlatamab clinical trial listings. US National Library of Medicine. Accessed April 2026.
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
2022;13(9):2945-2953.Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561.ClinicalTrials.gov. Tarlatamab clinical trial listings. US National Library of Medicine. Accessed
More news about: Amgen
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Engl J Med. 2012;366(6):539-551.Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702-714.Patel, N, et al. Poster Presentation at European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.
More news about: Amgen
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
2021 Sep 1;60(9):4029-4038. doi: 10.1093/rheumatology/keab364. PMID: 338781796 Beydon, M., et al. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024 Mar;20(3):158-169. doi: 10.1038/s41584-023-01057-6.7 Meudec L, Nocturne G, Mariette X. Update on the Aetiopathogenesis
More news about: Johnson & Johnson